✦ LIBER ✦

Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes

✍ Scribed by Harel Dahari; Evaldo S. Affonso de Araujo; Bart L. Haagmans; Thomas J. Layden; Scott J. Cotler; Antonio A. Barone; Avidan U. Neumann

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline risk factors for relapse in HIV

✍ A. Rivero-Juarez, J. A. Mira, A. Camacho, K. Neukam, I. Perez-Camacho… 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 190 KB

PEG IFN-α-2a/ribavirin a good pick for H

✍ Raewyn, Poole 📂 Article 📅 2004 🏛 Adis International Limited (now part of Wolters Kl ⚖ 175 KB

HCV clearance and treatment outcome in g

✍ Ana Moreno; Rafael Bárcena; Silvia García-Garzón; Alfonso Muriel; Carmen Quereda 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Very early prediction of response to HCV

✍ E. S. A. Araújo; H. Dahari; A. U. Neumann; N. de Paula Cavalheiro; C. E. Melo; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Multicenter comparison of PEG-IFN α2a or

✍ Young-Joo Jin, Jin-Woo Lee, Jung il Lee, Sang Hoon Park… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 274 KB

Efficacy and safety of peg-IFN alfa-2a w

✍ Maribel Rodríguez-Torres; José F. Rodríguez-Orengo; Carlos F. Ríos-Bedoya; Alber 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 183 KB